- Home
- BNTC vs AUTL Comparison
BNTC vs AUTL Comparison
Compare BNTC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | AUTL |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.2M | 385.9M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BNTC | AUTL |
|---|---|---|
| Price | $12.90 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $27.67 | $8.50 |
| AVG Volume (30 Days) | 140.6K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.85 | $1.18 |
| 52 Week High | $16.76 | $2.70 |
Technical Indicators
Market Signals| Indicator | BNTC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 40.09 |
| Support Level | $11.40 | $1.38 |
| Resistance Level | $13.48 | $1.52 |
| Average True Range (ATR) | 0.81 | 0.10 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 40.56 | 10.14 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.